BioInsights - Update on the Latest Developments in Viral and Non-Viral Vector Manufacturing - spotlight

CELL & GENE THERAPY INSIGHTS

Jan Thirkettle

Guest Editor:

Jan Thirkettle, Chief Executive Officer at Transine Therapeutics

November 2018

Co-sponsor

Update on the Latest Developments in Viral and Non-Viral Vector Manufacturing

Download PDF

Foreword

The latest developments in viral and non-viral vector manufacturing

The latest developments in viral and non-viral vector manufacturing

Jan Thirkettle

10 December 2018

Editorial

Update on the Sleeping Beauty transposon system for therapeutic applications

Update on the Sleeping Beauty transposon system for therapeutic applications

Suneel A Narayanavari

6 December 2018

Lentiviral vectors in hematopoietic stem cell therapies: mainstay technology, or simply a bridge to gene editing?

Lentiviral vectors in hematopoietic stem cell therapies: mainstay technology, or simply a bridge to gene editing?

Marc Moore, John R Counsell

30 November 2018

Expert Insight

Challenges and progress in lentiviral vector bioprocessing

Challenges and progress in lentiviral vector bioprocessing

E Macchiarulo, P Bassett, M Dudley

30 November 2018

Innovator Insight

Standardizing viral vector manufacture: maximizing production with the TRiP System<sup>TM</sup>

Standardizing viral vector manufacture: maximizing production with the TRiP System^TM

Interview

Transmission Electron Microscopy: a Critical Component of the Vector Analytical Toolkit

Transmission Electron Microscopy: a Critical Component of the Vector Analytical Toolkit

Vanessa Carvalho

17 December 2018

Joined-up thinking: success criteria for tomorrow’s viral vector production platforms

Joined-up thinking: success criteria for tomorrow’s viral vector production platforms

3 December 2018

Keeping viral vector manufacturing in-house: strategic considerations for gene therapy biotechs

Keeping viral vector manufacturing in-house: strategic considerations for gene therapy biotechs

Timothy J Miller

30 November 2018

Capacity or capability? Getting your priorities right in viral vector manufacturing

Capacity or capability? Getting your priorities right in viral vector manufacturing

Jan Thirkettle

30 November 2018

Applying learnings from the bioprocess development of Luxturna™

Applying learnings from the bioprocess development of Luxturna™

J. Fraser Wright

30 November 2018

Scaling up gene therapy manufacturing for multinational pivotal trials & commercialization

Scaling up gene therapy manufacturing for multinational pivotal trials & commercialization

Krzysztof Regulski

30 November 2018

AAV meets exosomes: at the cutting edge of cardiovascular gene therapy

AAV meets exosomes: at the cutting edge of cardiovascular gene therapy

Roger Hajjar

30 November 2018

Podcast

Joined-up thinking: success criteria for tomorrow’s viral vector production platforms

Joined-up thinking: success criteria for tomorrow’s viral vector production platforms

17 December 2018

Transmission Electron Microscopy: a Critical Component of the Vector Analytical Toolkit

Transmission Electron Microscopy: a Critical Component of the Vector Analytical Toolkit

Vanessa Carvahlo

3 December 2018

Conference Insight

The Growing Promise of Gene Therapy Approaches

The Growing Promise of Gene Therapy Approaches

J Grieger, R Snyder, J Samulski et al.

10 December 2018

Webinars

Scalable, helper virus-free AAV production with stable CAP-GT producer cell lines

Scalable, helper virus-free AAV production with stable CAP-GT producer cell lines

Nicole Faust

8 November 2018

Evaluation of Poros AAVX Pan-Affinity Resin for rAAV purification and cGMP Manufacturing

Evaluation of Poros AAVX Pan-Affinity Resin for rAAV purification and cGMP Manufacturing

Daniel Hurwit

18 December 2018